MTOR and systemic lupus erythematosus: Our results suggest that drugs related with inhibition of the mTOR and PI3K signaling pathways, and linked to anti-apoptotic and cell proliferation processes15, are the best candidates for Cluster 3, or lymphocyte-driven SLE.